Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

52 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
British Gynaecological Cancer Society/British Association of Gynaecological Pathology consensus for genetic testing in epithelial ovarian cancer in the United Kingdom.
Leung EY, Nicum S, Morrison J, Brenton JD, Funingana IG, Morgan RD, Ghaem-Maghami S, Miles T, Manchanda R, Bowen R, Andreou A, Loughborough W, Freeman S, Gajjar K, Coleridge S, Jimenez-Linan M, Balega J, Frost J, Keightley A, Wallis Y, Sundar S, Ganesan R. Leung EY, et al. Among authors: nicum s. Int J Gynecol Cancer. 2024 Sep 2;34(9):1334-1343. doi: 10.1136/ijgc-2024-005756. Int J Gynecol Cancer. 2024. PMID: 39222974
Colorectal cancer.
Nicum S, Midgley R, Kerr DJ. Nicum S, et al. Acta Oncol. 2003;42(4):263-75. doi: 10.1080/02841860310000412. Acta Oncol. 2003. PMID: 12899497 Review.
DNA-repair pathway inhibitors for the treatment of ovarian cancer.
Martinek I, Haldar K, Gaitskell K, Bryant A, Nicum S, Kehoe S, Morrison J. Martinek I, et al. Among authors: nicum s. Cochrane Database Syst Rev. 2010 Jun 16;(6):CD007929. doi: 10.1002/14651858.CD007929.pub2. Cochrane Database Syst Rev. 2010. Update in: Cochrane Database Syst Rev. 2015 May 20;(5):CD007929. doi: 10.1002/14651858.CD007929.pub3 PMID: 20556786 Free PMC article. Updated. Review.
ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease.
Colombo N, Sessa C, Bois AD, Ledermann J, McCluggage WG, McNeish I, Morice P, Pignata S, Ray-Coquard I, Vergote I, Baert T, Belaroussi I, Dashora A, Olbrecht S, Planchamp F, Querleu D; ESMO–ESGO Ovarian Cancer Consensus Conference Working Group. Colombo N, et al. Int J Gynecol Cancer. 2019 May 2:ijgc-2019-000308. doi: 10.1136/ijgc-2019-000308. Online ahead of print. Int J Gynecol Cancer. 2019. PMID: 31048403 Free article.
ICON 9-an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy.
Elyashiv O, Ledermann J, Parmar G, Farrelly L, Counsell N, Feeney A, El-Khouly F, Macdonald I, Neto A, Arthur-Darkwa E, Burnett E, Jayson GC, Mileshkin L, Gourley C, Nicum S. Elyashiv O, et al. Among authors: nicum s. Int J Gynecol Cancer. 2021 Jan;31(1):134-138. doi: 10.1136/ijgc-2020-002073. Epub 2020 Oct 23. Int J Gynecol Cancer. 2021. PMID: 33097567
British Gynaecological Cancer Society/British Association of Gynaecological Pathology consensus for germline and tumor testing for BRCA1/2 variants in ovarian cancer in the United Kingdom.
Sundar S, Manchanda R, Gourley C, George A, Wallace A, Balega J, Williams S, Wallis Y, Edmondson R, Nicum S, Frost J, Attygalle A, Fotopoulou C, Bowen R, Bell D, Gajjar K, Ramsay B, Wood NJ, Ghaem-Maghami S, Miles T, Ganesan R. Sundar S, et al. Among authors: nicum s. Int J Gynecol Cancer. 2021 Feb;31(2):272-278. doi: 10.1136/ijgc-2020-002112. Epub 2021 Jan 19. Int J Gynecol Cancer. 2021. PMID: 33468564 Review.
52 results